Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083396 | 0.86 | EP300 (0.57) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6626010 | 0.81 | SOAT1 (0.56) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7924678 | 0.77 | HSD17B10 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23281438 | 0.77 | GAA (0.60) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14282880 | 0.77 | EP300 (0.56) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10632785 | 0.77 | HDAC3 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9770492 | 0.77 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15894577 | 0.75 | EP300 (0.62) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14282873 | 0.75 | CETP (0.53) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14282881 | 0.75 | CETP (0.53) | EP300HDAC3HDAC1CETPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268372-B9 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2021-03-31 | — | — | EP | disclosed |
| CN-107548397-B | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200377514-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-12-03 | — | — | US | disclosed |
| US-10822345-B2 | KV1.3 inhibitors and their medical application | 4SC AG (DE) | 2020-11-03 | — | — | US | disclosed |
| US-20200339592-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-10-29 | — | — | US | disclosed |
| US-10723743-B2 | Kv1.3 inhibitors and their medical application | 4SC AG (DE) | 2020-07-28 | — | — | US | disclosed |
| EP-3268372-B1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-07-01 | — | — | EP | disclosed |
| CN-107548396-B | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2020-04-28 | — | — | CN | disclosed |
| US-20190352308-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS | 4SC AG (DE) | 2019-11-21 | — | — | US | disclosed |
| EP-3268374-B1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2019-09-25 | — | — | EP | disclosed |
| US-10399991-B2 | Kv1.3 inhibitors and their medical applications | 4SC AG (DE) | 2019-09-03 | — | — | US | disclosed |
| US-20190185483-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20180051034-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2018-02-22 | — | — | US | disclosed |
| EP-3268372-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2018-01-17 | — | — | EP | disclosed |
| EP-3268374-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2018-01-17 | — | — | EP | disclosed |
| CN-107548397-A | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2018-01-05 | — | — | CN | disclosed |
| CN-107548396-A | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2018-01-05 | — | — | CN | disclosed |
| US-20170369501-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS | 4SC AG (DE) | 2017-12-28 | — | — | US | disclosed |
| WO-2016146583-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC DISCOVERY GMBH (DE) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016146575-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC DISCOVERY GMBH (DE) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185483-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNA3, KCNN3, KCNK3 | EP300 1251/4885HDAC3 196/4885HDAC4 1494/4885 |
| US-20180051034-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNN3, KCNN2, KCNA3 | EP300 1743/4885HDAC3 274/4885HDAC4 1955/4885 |
| US-20190352308-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS | KCNA3, KCNN3, KCNH3 | EP300 3218/4885HDAC3 298/4885HDAC4 1961/4885 |
| US-20170369501-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS | KCNA3, KCNN3, KCNH3 | EP300 3218/4885HDAC3 298/4885HDAC4 1961/4885 |
| US-20200339592-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNA3, KCNN3, KCNK3 | EP300 1251/4885HDAC3 196/4885HDAC4 1494/4885 |
| US-10723743-B2 | Kv1.3 inhibitors and their medical application | KCNA3, KCNN3, KCNK3 | EP300 1251/4885HDAC3 196/4885HDAC4 1494/4885 |
| US-10822345-B2 | KV1.3 inhibitors and their medical application | KCNA3, KCNN3, KCNK3 | EP300 1251/4885HDAC3 196/4885HDAC4 1494/4885 |
| US-10399991-B2 | Kv1.3 inhibitors and their medical applications | KCNA3, KCNN3, KCNH3 | EP300 3218/4885HDAC3 298/4885HDAC4 1961/4885 |
| US-20200377514-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNN3, KCNN2, KCNA3 | EP300 1743/4885HDAC3 274/4885HDAC4 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.